International Guidelines for Bioequivalence of Systemically Available Orally Administered Generic Drug Products: A Survey of Similarities and Differences
Journal Title: The AAPS Journal - Year 2013, Vol 15, Issue 4
Abstract
The objective of this article is to discuss the similarities and differences among bioequivalence approaches used by international regulatory authorities when reviewing applications for marketing new generic drug products which are systemically active and intended for oral administration. We focused on the 13 jurisdictions and organizations participating in the International Generic Drug Regulators Pilot. These are Australia, Brazil, Canada, China, Chinese Taipei, the European Medicines Association, Japan, Mexico, Singapore, South Korea, Switzerland, the USA, and the World Health Organization. We began with a comparison of how the various jurisdictions and organizations define a generic product and its corresponding reference product. We then compared the following bioequivalence approaches: recommended bioequivalence study designs, method of pharmacokinetic calculations and bioequivalence acceptance limits, recommendations for modifying bioequivalence study designs and limits for highly variable drugs and narrow therapeutic index drugs, provisions for waiving bioequivalence study requirements (granting biowaivers), and implementation of the Biopharmaceutics Classification System. We observed that, overall, there are more similarities than differences in bioequivalence approaches among the regulatory authorities surveyed.
Authors and Affiliations
Barbara Davit, April C. Braddy, Dale P. Conner, Lawrence X. Yu
Keywords
Related Articles
- EP ID EP681154
- DOI 10.1208/s12248-013-9499-x
- Views 131
- Downloads 0
Effect of Censoring Due to Progressive Disease on Tumor Size Kinetic Parameter Estimates
Tumor growth profiles were simulated for 2 years using the Wang and Claret models under a phase 3 clinical trial design. Profiles were censored when tumor size increased >20% from nadir similar to clinica...
Peptide Amphiphile Micelles Self-Adjuvant Group A Streptococcal Vaccination
Delivery system design and adjuvant development are crucially important areas of research for improving vaccines. Peptide amphiphile micelles are a class of biomaterials that have the unique potential to function as both...
CDER Risk Assessment Exercise to Evaluate Potential Risks from the Use of Nanomaterials in Drug Products
The Nanotechnology Risk Assessment Working Group in the Center for Drug Evaluation and Research (CDER) within the United States Food and Drug Administration was established to assess the possible impact of nanotechnology...
In Vitro, Pharmacokinetic, Pharmacodynamic, and Safety Comparisons of Single and Combined Administration of Tiotropium and Salmeterol in COPD Patients Using Different Dry Powder Inhalers
The online version of this article (doi:10.1208/s12248-015-9751-7) contains supplementary material, which is available to authorized users.
A Sequential Bioequivalence Design with a Potential Ethical Advantage
The online version of this article (doi:10.1208/s12248-014-9622-7) contains supplementary material, which is available to authorized users.